The agency opened a 60-day comment period on the information collection relating to human drug compounding under sections 503A and 503B of the Act.
Washington, 26 May 2026 — The Food and Drug Administration announced an opportunity for public comment on a proposed collection of information relating to human drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The notice runs under the Paperwork Reduction Act of 1995, which requires a 60-day comment window on each proposed collection.
Source documents
-
Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
- Identifier
- Federal Register document 2026-10372
- As the record states
- The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection relating to human drug compounding.
- Document number
- 2026-10372